Authorized purpose: Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.
Clinical role
Adjunctive tracked-ultrasound acquisition, three-dimensional reconstruction, and scoliosis-angle measurement.
Images and patients
Ultrasound · Spine
Key limitation
Keep in mind: Use is adjunctive to conventional imaging and not the sole basis for patient management. The FDA study included 31 test subjects and showed larger mean absolute measurement differences in the greater-than-40-degree curvature subgroup.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Spine Input: B-mode spinal ultrasound acquired with the tracked SpineUs transducer and compatible ultrasound components.
Who uses it?Intended users: Trained chiropractors and radiologists qualified to perform and interpret musculoskeletal ultrasound.
What does the software produce?Output: Three-dimensional reconstructed spinal images, AI-segmented bone surfaces, and user-reviewed scoliosis-angle measurements.
What is its most important limitation?Key limitation: Use is adjunctive to conventional imaging and not the sole basis for patient management. The FDA study included 31 test subjects and showed larger mean absolute measurement differences in the greater-than-40-degree curvature subgroup.
Clinical takeaway. Clinical role: Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.
Evidence takeaway. Evidence from the reviewed source record: FDA-described testing used a 31-subject test set independent from development data. Transverse processes were identified in all test cases; pixel-level bone segmentation sensitivity was 41.80% and specificity was 99.19%. Three observers compared ultrasound and radiograph scoliosis-angle measurements, with mean absolute differences increasing in the greater-than-40-degree curvature subgroup.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Tracked B-mode ultrasound acquisition, display, and scoliosis-angle measurement of the spine for trained users as an adjunct to conventional imaging; it is not the sole basis for patient management.
Use is adjunctive to conventional imaging and not the sole basis for patient management. The FDA study included 31 test subjects and showed larger mean absolute measurement differences in the greater-than-40-degree curvature subgroup.
FDA-described testing used a 31-subject test set independent from development data. Transverse processes were identified in all test cases; pixel-level bone segmentation sensitivity was 41.80% and specificity was 99.19%. Three observers compared ultrasound and radiograph scoliosis-angle measurements, with mean absolute differences increasing in the greater-than-40-degree curvature subgroup.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA-described testing used a 31-subject test set independent from development data. Transverse processes were identified in all test cases; pixel-level bone segmentation sensitivity was 41.80% and specificity was 99.19%. Three observers compared ultrasound and radiograph scoliosis-angle measurements, with mean absolute differences increasing in the greater-than-40-degree curvature subgroup.
SpineUs segmentation and scoliosis-angle validation
DesignIndependent test-set evaluation of AI bone-surface segmentation and three-observer comparison of ultrasound and radiograph scoliosis-angle measurements.
Population31 subjects spanning less-than-20-degree, 20-to-40-degree, and greater-than-40-degree spinal-curvature subgroups.
Scopeexact submission
Tested versionSpineUs configuration submitted in K241029
Samplen=31
IndependenceSponsor or vendor study
K241029
FDA submission evidence; not an independent clinical-outcomes study.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241029. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: B-mode spinal ultrasound acquired with the tracked SpineUs transducer and compatible ultrasound components.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The cleared system combines a tracked ultrasound transducer, workstation software, and B-mode input; the reviewed FDA summary does not establish PACS, RIS, or EHR interfaces.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Three-dimensional reconstructed spinal images, AI-segmented bone surfaces, and user-reviewed scoliosis-angle measurements.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Three-dimensional reconstructed spinal images, AI-segmented bone surfaces, and user-reviewed scoliosis-angle measurements.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The cleared system combines a tracked ultrasound transducer, workstation software, and B-mode input; the reviewed FDA summary does not establish PACS, RIS, or EHR interfaces.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
20Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K241029 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Accuro 3S is portable B-mode ultrasound with SpineNav-AI for lumbar-spine scouting and epidural-depth estimation during neuraxial-anesthesia and needle or catheter placement workflows.
Authorized purpose: EdgeFlow UW20 is a wearable ultrasound system for noninvasive periodic bladder-volume measurement in adults with BMI no greater than 30.
Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.